<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Meniere disease: Evaluation, diagnosis, and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Meniere disease: Evaluation, diagnosis, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Meniere disease: Evaluation, diagnosis, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard S Moskowitz, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth A Dinces, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel G Deschler, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Meniere disease (MD), named for French physician Prosper Menière, is a condition characterized by episodic vertigo, tinnitus, and hearing loss [<a href="#rid1">1</a>].</p><p>This topic will present an overview of the diagnosis and treatment of MD. More detailed topics addressing the differential diagnosis of vertigo, tinnitus, and hearing loss are presented separately. (See  <a class="medical medical_review" href="/d/html/5094.html" rel="external">"Evaluation of the patient with vertigo"</a> and  <a class="medical medical_review" href="/d/html/5101.html" rel="external">"Causes of vertigo"</a> and  <a class="medical medical_review" href="/d/html/6855.html" rel="external">"Etiology and diagnosis of tinnitus"</a> and  <a class="medical medical_review" href="/d/html/6844.html" rel="external">"Etiology of hearing loss in adults"</a> and  <a class="medical medical_review" href="/d/html/6847.html" rel="external">"Sudden sensorineural hearing loss in adults: Evaluation and management"</a>.)</p><p class="headingAnchor" id="H4237257924"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meniere disease</strong> – The classic triad of symptoms (episodic vertigo, tinnitus, and hearing loss), likely caused by endolymphatic hydrops of the labyrinthine system of the inner ear. (See <a class="local">'Pathogenesis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meniere syndrome</strong> – The symptomatic triad of episodic vertigo, tinnitus, and hearing loss occurring secondary to other inner ear disorders.</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Meniere disease (MD) may occur at any age, but symptoms typically begin between the ages of 20 and 40 years.</p><p>Meniere syndrome in children is most often associated with congenital malformations of the inner ear [<a href="#rid2">2,3</a>], and in adults it may be caused by acquired otologic disease  (<a class="graphic graphic_table graphicRef50362" href="/d/graphic/50362.html" rel="external">table 1</a>). (See <a class="local">'Differential diagnosis'</a> below.)</p><p>The incidence of MD is difficult to determine because of the lack of widely accepted diagnostic criteria but ranges from 10 to 150 per 100,000 persons [<a href="#rid4">4</a>]. Among patients with MD, bilateral disease occurs in 10 to 50 percent of patients [<a href="#rid5">5-7</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The classic pathologic lesion of Meniere disease (MD) is termed endolymphatic hydrops, which can only be definitively diagnosed by postmortem histopathologic analysis of the temporal bone. However, while endolymphatic hydrops is present in all patients with MD, not all patients with endolymphatic hydrops are symptomatic. In some studies, the degree of hearing loss, but not other clinical features of MD (eg, vertigo, tinnitus), may correlate with the severity of endolymphatic hydrops [<a href="#rid8">8</a>]; thus, the exact mechanism responsible for all of the symptoms of MD is unknown.</p><p>Endolymphatic hydrops can cause distortion and distention of the membranous, endolymph-containing portions of the labyrinthine system  (<a class="graphic graphic_figure graphicRef126296" href="/d/graphic/126296.html" rel="external">figure 1</a>). Although most patients with endolymphatic hydrops have no identifiable additional otologic disease, multiple potential causes have been proposed  (<a class="graphic graphic_table graphicRef50362" href="/d/graphic/50362.html" rel="external">table 1</a>). In affected patients, is unclear why excess fluid builds up in the endolymphatic spaces of the inner ear. Lack of a single etiologic cause may reflect underlying clinical and genetic heterogeneity in MD [<a href="#rid9">9</a>].</p><p>Proposed etiologies include:</p><p class="bulletIndent1"><span class="glyph">●</span>One theory postulates an abnormality in the flow of endolymph or resorption of endolymph at the endolymphatic sac. Endolymphatic hydrops has been experimentally induced in animals by blocking the entrance to the endolymphatic sac [<a href="#rid10">10</a>]. In another hypothesis, endolymphatic hydrops may begin as a result of detached saccular otoconia (calcium deposits), which may block the normal flow of endolymph. This mechanism has also been postulated as the cause of benign paroxysmal positional vertigo [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/5098.html" rel="external">"Benign paroxysmal positional vertigo", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypoplasia of the vestibular aqueduct [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An immunologic mechanism, with autoantibodies against some component of the endolymphatic sac [<a href="#rid13">13-15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An autosomal dominant inheritance pattern has been observed in 8 to 15 percent of patients with MD [<a href="#rid16">16,17</a>], raising the possibility of a genetic etiology. Among patients with a family history, earlier age of onset and more severe symptoms were observed in successive generations [<a href="#rid16">16</a>]. No specific gene has been identified, however.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Migraine occurs more commonly in patients with MD than in the general population, leading to the postulation of a common vascular pathophysiology for the two disorders [<a href="#rid18">18,19</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3430757487"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>The course of Meniere disease (MD) is variable. Some patients experience progressive hearing loss with infrequent vestibular symptoms; some have severe and frequent vertigo with only mild auditory symptoms; and some manifest both auditory and vestibular symptoms in equal measure. Approximately two-thirds of patients experience vertigo attacks in clusters, while one-third have sporadic attacks. The frequency of vertigo episodes may decline over time [<a href="#rid20">20</a>]. Most patients tend to cycle from active symptoms to prolonged remissions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vertigo </strong>–<strong> </strong>The vertigo is typically described as a rotatory spinning or rocking, may be associated with nausea and vomiting, and persists from 20 minutes to 24 hours [<a href="#rid21">21</a>]. Additional sensations of disequilibrium or other patterns of dizziness are seen in about 15 percent of cases; the sense of disequilibrium may persist between acute vertigo attacks. (See  <a class="medical medical_review" href="/d/html/5094.html" rel="external">"Evaluation of the patient with vertigo"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hearing loss</strong> – Early in the presentation, hearing loss usually fluctuates and often initially affects only the lower frequencies [<a href="#rid22">22</a>]. Hearing loss typically progresses and often results in permanent hearing loss at all frequencies in the affected ear over the subsequent 8 to 10 years. Episodes of hearing loss are typically associated with intense ipsilateral aural fullness or head pressure [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/6844.html" rel="external">"Etiology of hearing loss in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tinnitus</strong> – Tinnitus may be fluctuating or constant, with variable pitch and intensity. Tinnitus may occur concurrent or independent of auditory symptoms or vertigo. (See  <a class="medical medical_review" href="/d/html/6855.html" rel="external">"Etiology and diagnosis of tinnitus"</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Diagnostic criteria and testing</span><span class="headingEndMark"> — </span>A clinical diagnosis of MD is made based upon the following criteria [<a href="#rid23">23-25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Two or more spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours</p><p class="bulletIndent1"><span class="glyph">●</span>Audiometrically documented low- to mid-frequency sensorineural hearing loss in the affected ear</p><p class="bulletIndent1"><span class="glyph">●</span>Fluctuating aural symptoms (reduced or distorted hearing, tinnitus, or fullness) in the affected ear</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms not better accounted for by another vestibular diagnosis</p><p></p><p>Patients typically have auditory and/or vestibular symptoms for three to five years before they meet the diagnostic criteria for MD; a large time gap between episodes may preclude a more rapid diagnosis.</p><p>Although audiometric testing is a required part of the diagnostic evaluation, there is no specific diagnostic test for MD. Other tests commonly used in the evaluation of patients with symptoms of MD include imaging and vestibular testing. Imaging, although not required for diagnosis of MD, is frequently performed to exclude important disorders that can present with similar symptoms (eg, vestibular schwannoma). (See <a class="local">'Differential diagnosis'</a> below.)</p><p>A review of the testing and test results in patients with MD are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Audiometry – Audiometry is a necessary part of the evaluation in all patients with suspected MD [<a href="#rid26">26</a>]. The most common audiometric pattern in early MD is a low-frequency or combined low- and high-frequency sensorineural hearing loss with normal hearing in the mid-frequencies. Over time, the hearing loss "flattens out" with hearing loss in all frequency ranges.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vestibular testing – Vestibular testing, if performed, may be normal early in the course of the disease but will eventually become abnormal on the affected side. Vestibular testing is not mandatory; it is primarily useful in determining candidacy for interventional treatments in patients with more severe or persistent symptoms.</p><p></p><p class="bulletIndent1">Vestibular evaluation includes electronystagmography (ENG), rotary chair testing, and computerized dynamic posturography. With progression of MD, both the ENG and rotary chair test will likely show declining peripheral vestibular function in the affected ear. The ENG (particularly the caloric test, in which the ear canals are irrigated with warm and cool water to stimulate the inner ear) is more sensitive for inner balance dysfunction, but the rotary chair test is more specific. (See  <a class="medical medical_review" href="/d/html/5094.html" rel="external">"Evaluation of the patient with vertigo", section on 'Electronystagmography and video nystagmography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging – Magnetic resonance imaging (MRI) of the temporal bone can identify features that support a diagnosis of MD (eg, less prominent endolymphatic duct), but the findings are not diagnostic [<a href="#rid27">27</a>]. Nevertheless, MRI (or computed tomography [CT] if MRI is contraindicated) is typically done to rule out central nervous system (CNS) lesions that can mimic MD, including tumors, aneurysms or stenosis of the posterior circulation, Arnold-Chiari malformations, and multiple sclerosis. (See  <a class="medical medical_review" href="/d/html/5309.html" rel="external">"Principles of magnetic resonance imaging", section on 'Precautions'</a> and <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other tests – Other testing may be used as part of the evaluation of MD, but these tests are not standardized and are not widely available for clinical use.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tests for antibodies against inner ear antigens exist [<a href="#rid28">28-30</a>], but they are not considered to be clinically useful and are not part of a routine evaluation for MD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There are tests for endolymphatic hydrops, which include glycerine, urea, or <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a> "stress" tests [<a href="#rid31">31</a>] and electrocochleography [<a href="#rid32">32</a>]. However, these tests have low sensitivity and specificity, and their role in the diagnosis and management of MD is controversial.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The vestibular evoked myogenic potential (VEMP) is a test that shows promise for diagnosis and monitoring [<a href="#rid33">33</a>]. Cervical VEMP (cVEMP) is an inhibitory sacculocolic reflex test that shows characteristic changes in symptomatic ears of patients with MD [<a href="#rid33">33</a>] and may detect early saccular hydrops before the onset of classic Meniere symptoms [<a href="#rid34">34</a>]. Ocular VEMP (oVEMP) engages both utricular and saccular afferent nerve fibers and may also be useful in assessment of Meniere patients [<a href="#rid35">35</a>]. In addition to diagnosis, VEMP may be useful for monitoring patients for disease progression and to identify the active ear in patients with bilateral disease. However, VEMP is an emerging technology that has not yet been standardized or fully validated clinically. (See  <a class="medical medical_review" href="/d/html/5094.html" rel="external">"Evaluation of the patient with vertigo", section on 'Vestibular evoked myogenic potentials'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A variety of other conditions can present with symptoms similar to Meniere disease (MD) and are often considered in the differential diagnosis  (<a class="graphic graphic_table graphicRef63235" href="/d/graphic/63235.html" rel="external">table 2</a>). Such conditions include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Migraine (migrainous vertigo or vestibular migraine)</strong> – The prevalence of migrainous vertigo, or vestibular migraine, is approximately 3 to 5 percent in the general population, higher than the 0.2 percent prevalence of MD in the United States population [<a href="#rid36">36</a>]. Migraine-associated vertigo is an important consideration, especially among those with a history of migraine headache, and in young patients with new onset of episodic vertigo [<a href="#rid37">37</a>]. Thus, among those with vertigo, migraine should always be considered as an alternative diagnosis or coexisting condition.</p><p></p><p class="bulletIndent1">In cases of vestibular migraine, headache may occur during or following the vertigo (in which case vertigo is considered the migraine aura). Vestibular migraine is often accompanied by photophobia or phonophobia, symptoms not seen in vertigo attacks associated with MD. Diagnostic criteria for vestibular migraine include episodic vestibular symptoms and at least two migraine symptoms (migrainous headache, photophobia, phonophobia, or visual or other aura) occurring during at least two vertiginous episodes [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/3356.html" rel="external">"Vestibular migraine", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1">Successful treatment with triptans during an attack is generally diagnostic, although the vertigo symptom is less responsive than the headache. The evaluation and diagnosis of vestibular migraine is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3356.html" rel="external">"Vestibular migraine", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vestibular schwannoma</strong> – Patients with vestibular schwannoma (acoustic neuroma) typically present with progressive asymmetric hearing loss but may occasionally have fluctuating hearing loss. These patients rarely have true vertigo but may complain of imbalance or disequilibrium. Occasional patients with vestibular schwannoma will have tinnitus and imbalance but no hearing loss. Among patients with vestibular schwannoma, auditory brainstem response (auditory evoked response) testing and magnetic resonance imaging (MRI) show abnormalities indicating compression of the eighth nerve complex. (See  <a class="medical medical_review" href="/d/html/5222.html" rel="external">"Vestibular schwannoma (acoustic neuroma)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple sclerosis</strong> – Multiple sclerosis (MS) can present with symptoms identical to those of MD. However, during an attack of MS with vertigo, the observed nystagmus is typically more severe and longer lasting than in patients with MD, and patients with MS may have additional neurologic complaints. On electronystagmogram (ENG) testing, central abnormalities are often seen in patients with MS but are typically absent in early MD. In MS, white matter lesions may be seen on brain MRI and cerebrospinal fluid abnormalities may be detected; these findings are absent in patients with MD. (See  <a class="medical medical_review" href="/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transient ischemic attack</strong> – Although transient ischemic attacks (TIAs) may present with similar symptoms, there are differences which distinguish them from MD attacks. Symptoms due to TIAs are typically shorter in duration than attacks of MD. Patients with TIAs rarely experience simultaneous vestibular and cochlear symptoms, while these commonly occur together in MD. TIAs do not cause persistent or recurrent tinnitus or objective hearing loss, while these are common in MD. (See  <a class="medical medical_review" href="/d/html/1123.html" rel="external">"Initial evaluation and management of transient ischemic attack and minor ischemic stroke"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign paroxysmal positional vertigo</strong> – Patients with benign paroxysmal positional vertigo (BPPV) also have recurrent attacks of vertigo, but unlike that in MD, the vertigo is typically precipitated by head movements and brief in duration. Additionally, in BPPV, hearing symptoms are absent. (See  <a class="medical medical_review" href="/d/html/5098.html" rel="external">"Benign paroxysmal positional vertigo", section on 'Symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cogan syndrome</strong> – Cogan syndrome is a chronic inflammatory condition seen most commonly in young adults, and is characterized by ocular disease, vasculitis, and vestibuloauditory symptoms similar to those seen in MD. The clinical features, evaluation, and diagnosis of Cogan syndrome is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/8227.html" rel="external">"Cogan syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions</strong> – Chronic conditions such as diabetes, anemia, and thyroid disease may cause symptoms that have some overlap with features of MD, including tinnitus and chronic disequilibrium, although true vertigo is not typical. In addition, these comorbid conditions may affect the severity of MD.</p><p></p><p class="headingAnchor" id="H1583563988"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Determining the optimal treatment regimen for Meniere disease (MD) is limited by the lack of high-quality data [<a href="#rid9">9,39</a>]. The relapsing and remitting nature of the disorder makes comparisons of various treatments difficult.</p><p class="headingAnchor" id="H12"><span class="h2">Goals and patient expectations</span><span class="headingEndMark"> — </span>Treatment of MD may improve or relieve symptoms but does not correct the underlying abnormal pathophysiology. Patient education is an important part of management and includes an explanation of the disease and its natural history, review of treatment options, and expectations regarding response to treatment.</p><p>The goals of treatment are to improve the patient's quality of life by [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Reducing the frequency and severity of vertigo attacks</p><p class="bulletIndent1"><span class="glyph">●</span>Reducing or eliminating the tinnitus and hearing loss associated with attacks</p><p class="bulletIndent1"><span class="glyph">●</span>Alleviating chronic symptoms of tinnitus and disequilibrium</p><p class="bulletIndent1"><span class="glyph">●</span>Minimizing disability associated with MD</p><p class="bulletIndent1"><span class="glyph">●</span>Preventing progressive hearing loss </p><p></p><p>With noninvasive management (including dietary modification/lifestyle adjustment, medications, and vestibular rehabilitation), up to 90 percent of patients with MD are able to maintain normal daily activities. Vertigo attacks can be controlled in 90 to 95 percent of patients with treatment; patients with suspected MD should be referred at a relatively early stage to an otolaryngologist to control attacks and minimize progression of hearing loss. </p><p class="headingAnchor" id="H13"><span class="h2">Initial diet and lifestyle adjustment for all patients</span><span class="headingEndMark"> — </span>Initial therapy for all patients with MD includes dietary and lifestyle adjustments.</p><p>Patients with MD are more vulnerable to dietary and environmental factors, and triggers may include high salt intake, caffeine, alcohol, nicotine, stress, monosodium glutamate (MSG), and allergies (food and environmental) [<a href="#rid40">40</a>]. Among patients with identified triggers, avoidance or minimization of exposure to these substances, as well as treatment for allergies if appropriate, may alleviate or ameliorate symptoms.</p><p>We suggest salt restriction as part of initial therapy for all patients [<a href="#rid23">23,41,42</a>], although there is a lack of high-quality data supporting the efficacy of this approach [<a href="#rid9">9,40</a>]. An appropriate salt-restricted diet will include a maximum of 2 to 3 g of sodium daily, with the daily sodium intake evenly spread across meals to avoid a large bolus at any time. (See  <a class="medical medical_patient" href="/d/html/4411.html" rel="external">"Patient education: Low-sodium diet (Beyond the Basics)"</a>.)</p><p>In addition, we suggest limiting caffeine and alcohol consumption to one caffeinated beverage (coffee, tea, or cola) and one alcoholic drink daily, particularly if these are triggers for attacks. Caffeine and nicotine are vasoconstrictors that may reduce microvascular flow in the labyrinthine system. Similarly, alcohol causes fluid and electrolyte shifts that may stress a vulnerable ear. </p><p>We advise that patients with MD continue the above dietary and lifestyle adjustments indefinitely.</p><p class="headingAnchor" id="H1533157828"><span class="h2">Vestibular rehabilitation for residual disequilibrium between attacks</span><span class="headingEndMark"> — </span>We suggest referring patients with MD and persistent disequilibrium symptoms between attacks for vestibular rehabilitation therapy. Vestibular rehabilitation uses exercise activities to maximize balance and central nervous system (CNS) compensation for disequilibrium symptoms.</p><p>Although vestibular rehabilitation has been used primarily in patients whose vertigo has responded to medical or surgical treatment but who have residual disequilibrium [<a href="#rid43">43</a>], it may also be used for any patient with MD who experiences significant balance and disequilibrium symptoms between acute vertigo attacks [<a href="#rid9">9</a>]. Participation in vestibular rehabilitation therapy does not reduce the frequency or severity of vertigo attacks. </p><p>Further, vestibular rehabilitation has no role in the management of acute vertigo due to MD [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H3711595859"><span class="h2">Pharmacotherapy for patients with refractory symptoms</span><span class="headingEndMark"> — </span>A number of medications have been used to treat MD, both to reduce the intensity and severity of attacks and to treat acute vertigo. Daily vasodilator or diuretic therapy with as-needed vestibular suppressants and antiemetics are typically used when dietary and lifestyle adjustments alone do not adequately control the episodes. In the majority of patients, combinations of these agents can control episodes of vertigo or decrease their severity, although they have not been shown to prevent hearing loss [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H2017340077"><span class="h3">Chronic management with chronic betahistine or diuretic therapy</span><span class="headingEndMark"> — </span>In patients with MD with a poor quality of life due to refractory symptoms (ie, recurrent vertigo) despite dietary and lifestyle interventions, we suggest the use of pharmacotherapy rather than no pharmacotherapy.</p><p><a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">Betahistine</a> (a vasodilator available in Europe, Central and South America, and Canada, and as a compounded preparation in the United States), and diuretics are the two pharmacologic options to reduce the severity and intensity of attacks. We suggest treatment with betahistine rather than diuretics when available because it is well tolerated and does not require monitoring of metabolic effects, including blood pressure, kidney function, and electrolytes. However, when betahistine is unavailable, we treat these patients with chronic diuretic therapy.</p><p>If <a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">betahistine</a> is selected, the typical maintenance dose is 8 to 16 mg orally three times daily. We generally begin with once-daily dosing and evaluate the patient's response at –two- to four-week intervals; if there is insufficient control of symptoms, we increase to twice daily, and then to three times daily if needed. Maintaining patients on twice-daily dosing is also an option [<a href="#rid45">45</a>].</p><p>If a diuretic is selected, we typically prescribe <a class="drug drug_general" data-topicid="8530" href="/d/drug information/8530.html" rel="external">hydrochlorothiazide-triamterene</a> 25 mg/37.5 mg orally once daily. Other diuretic options include <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a> 20 mg orally once daily or <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> 250 to 500 mg orally twice daily.</p><p>Concomitant treatment with both <a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">betahistine</a> and a diuretic is also an option [<a href="#rid23">23</a>], although this is less frequently used. Some experts add a second agent if there is insufficient control of symptoms on a single agent, although there are no high-quality data to support this approach.</p><p>For patients who respond to treatment with <a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">betahistine</a> or a diuretic, treatment is continued for approximately six months; if symptoms remain well controlled, the medication can be tapered (for betahistine) and discontinued. Pharmacotherapy can be resumed if troublesome symptoms recur.</p><p>There are no high-quality data on the efficacy of these medications. However, these medications are widely used due to possible benefit and the low risk of adverse effects. Although early trials demonstrated efficacy of both <a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">betahistine</a> and diuretics in the control of vertigo symptoms [<a href="#rid46">46</a>], two subsequent systematic reviews found methodologic flaws in the included studies and determined that there was insufficient evidence to establish efficacy [<a href="#rid47">47,48</a>]. In addition, in a subsequent randomized trial comparing placebo with low- and high-dose betahistine, there was no difference in the incidence of attacks between the three groups [<a href="#rid49">49</a>].</p><p>Theoretically, <a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">betahistine</a> and diuretics may reduce the degree of endolymphatic hydrops. Betahistine is thought to act by improving microvascular circulation in the stria vascularis of the cochlea or by inhibiting vestibular nuclei activity [<a href="#rid41">41,46,50,51</a>]. Diuretics are thought to improve endolymph resorption and also maintain a balanced fluid dynamic in the endolymphatic system, particularly when used in conjunction with sodium restriction.</p><p>Appropriate monitoring for renal function, electrolytes, and blood pressure should be performed for any patient on chronic diuretic therapy, with particular cautions about the risks of orthostasis in older adults. (See  <a class="medical medical_review" href="/d/html/2288.html" rel="external">"Diuretic-induced hyponatremia"</a> and  <a class="medical medical_review" href="/d/html/2356.html" rel="external">"Time course of loop and thiazide diuretic-induced electrolyte complications"</a> and  <a class="medical medical_review" href="/d/html/5103.html" rel="external">"Mechanisms, causes, and evaluation of orthostatic hypotension", section on 'Medications'</a>.)</p><p class="headingAnchor" id="H9651091"><span class="h3">Acute treatment with vestibular suppressants and antiemetics</span><span class="headingEndMark"> — </span>Acute episodes of vertigo should be managed with vestibular suppressants and antiemetics if necessary  (<a class="graphic graphic_table graphicRef68052" href="/d/graphic/68052.html" rel="external">table 3</a>). The lowest effective medication dose should be used, and the potential adverse effects (including the risk of sedation) should be considered. (See  <a class="medical medical_review" href="/d/html/5097.html" rel="external">"Treatment of vertigo"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with MD (managed with dietary and lifestyle adjustments with or without chronic <a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">betahistine</a> or diuretic pharmacotherapy), we use benzodiazepine vestibular suppressants to treat episodic acute vertigo attacks. We use <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a> 0.25 mg to 0.5 mg orally two to three times daily as needed, or <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> 1 to 5 mg orally twice daily as needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe nausea or vomiting associated with acute vertigo attacks, we treat with <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a> 12.5 to 25 mg orally every six to eight hours as needed, or <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> 4 mg orally two to three times daily as needed.</p><p></p><p class="bulletIndent1">For patients not able to tolerate oral medications, <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a> may be administered rectally or intramuscularly (IM); intravenous (IV) administration is also an option, although is generally not preferred due to risk of extravasation injury. <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">Ondansetron</a> may be administered IV.</p><p></p><p class="bulletIndent1">For the patient with acute vertigo and persistent vomiting, in addition to antiemetic treatment, assessment of volume status and with appropriate volume repletion is appropriate.</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Refractory, disabling symptoms despite initial pharmacotherapy</span><span class="headingEndMark"> — </span>Approximately 10 percent of patients with MD have intractable, unremitting, or progressive symptoms that significantly impair their quality of life despite the addition of initial pharmacotherapy (<a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">betahistine</a> or diuretic) to dietary and lifestyle adjustments. Patients with a continued poor quality of life due to MD symptoms despite three months of pharmacotherapy are candidates for additional treatments.</p><p>Among patients with severe symptoms, there are criteria available to quantify the severity of their functional impairment. As an example, there is a self-assessment tool, the Meniere Disease Functional Level Scale  (<a class="graphic graphic_table graphicRef72837" href="/d/graphic/72837.html" rel="external">table 4</a>), which is useful in evaluating the severity of MD symptoms before treatment as well as assessing the efficacy of therapy.</p><p>Separate criteria for evaluating occupational disability due to MD also exist [<a href="#rid52">52</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild – Intermittent or continuous dizziness/unsteadiness that precludes working in a hazardous environment</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Intermittent or continuous dizziness that results in a sedentary occupation</p><p class="bulletIndent1"><span class="glyph">●</span>Severe disability – Symptoms so severe as to exclude gainful employment</p><p></p><p>For patients with symptoms severe enough to require further treatment, there is no widely accepted agreement on which treatment is preferred. Our approach is as follows:</p><p class="headingAnchor" id="H3928817143"><span class="h3">Continue pharmacotherapy with betahistine or diuretcs if beneficial</span><span class="headingEndMark"> — </span>Regarding the continuation of pharmacotherapy in patients with refractory symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who experience any degree of symptomatic improvement with <a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">betahistine</a> or diuretic therapy, the medication is continued. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those patients who experience <strong>no</strong> improvement in symptoms with such pharmacotherapy, the medication is discontinued. </p><p></p><p class="headingAnchor" id="H1755326271"><span class="h3">Glucocorticoid therapy for all patients with refractory, disabling symptoms</span><span class="headingEndMark"> — </span>For all patients with refractory MD, (including those who continue to take <a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">betahistine</a> or diuretics and those in whom such pharmacotherapy is discontinued), we suggest treatment with glucocorticoids rather than other therapies. Glucocorticoid treatment options include systemic or intratympanic administration. (See <a class="local">'Systemic glucocorticoids'</a> below and <a class="local">'Intratympanic glucocorticoids'</a> below.)</p><p>Although intratympanic administration of glucocorticoids may have slightly better efficacy, oral administration is generally better tolerated and preferred by most patients.</p><p>In addition to considering the patient's preferences, we evaluate their medical comorbidities, considering any possible contraindications to a short course of high dose oral glucocorticoids. For those patients in whom systemic glucocorticoid therapy is contraindicated, we treat with intratympanic glucocorticoids. </p><p class="headingAnchor" id="H3631334235"><span class="h4">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>For the majority of patients with MD, hearing loss, and refractory, disabling vertigo symptoms despite first-line treatments, we treat with a limited course of oral glucocorticoids [<a href="#rid53">53</a>]. </p><p>We typically treat with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg daily, for a maximum dose of 60 mg orally once daily, for 7 to 14 days.</p><p>The use of systemic glucocorticoid therapy for MD is based upon the possible immunologic etiology of the disease and the efficacy of steroid therapy in the treatment of sudden sensorineural hearing loss [<a href="#rid9">9</a>]. This noninvasive treatment is often preferred by patients to invasive treatment options.</p><p>For those patients in whom high-dose glucocorticoid therapy may present a medical management issue (eg, insulin dependent diabetes), we would prescribe in consultation with the patient's primary care clinician or appropriate specialist. Additionally, we would not use this treatment in those patients for whom systemic glucocorticoids are contraindicated due to intolerance or comorbidity. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H568696140"><span class="h4">Intratympanic glucocorticoids</span><span class="headingEndMark"> — </span>For patients with MD with disabling vertigo symptoms despite first-line treatments, and in whom oral glucocorticoid therapy is contraindicated, or who through shared decision making prefer intratympanic therapy, we offer treatment with intratympanic glucocorticoids. </p><p>With this technique, a glucocorticoid solution is delivered into the middle ear space by injection or cannula. We administer an initial intratympanic <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> injection, approximately 0.3 mL of a 10 to 24 mg/mL solution (available preparations vary from 4 to 10 mg/mL for a traditional solution to 24 to 40 mg/mL for the compounded preparation) into the affected ear, and we may repeat injections at once weekly intervals for an additional one to two injections based upon the patient's response. If there is no improvement in vertigo after three injections, we discontinue this treatment and move on to other available therapies for patients with preserved hearing. We routinely check an audiogram after completion of the injection protocol or at any point if the patient reports an increase in tinnitus or decrease in hearing.</p><p>Treatment with intratympanic glucocorticoids is based upon the possible immunologic basis of MD. As in systemic therapy, there is no ototoxicity associated with this treatment [<a href="#rid9">9</a>].</p><p>In prospective studies of patients with MD, there were improvements in vertigo and functional scores following intratympanic <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> injections [<a href="#rid54">54,55</a>]. The benefits may be maintained over time (6 to 24 months), although patients may require repeat injections and the efficacy of subsequent injections may decrease [<a href="#rid55">55-57</a>].</p><p>Although intratympanic <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> may not be as effective as intratympanic <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> for control of vertigo, there may be a slight improvement in hearing in some treated patients. As an example, in a trial comparing low-dose intratympanic gentamicin and intratympanic dexamethasone, control of vertigo was greater for the gentamicin group, but among those in the dexamethasone group with complete vertigo control, there was no loss, and even slight improvement in hearing [<a href="#rid58">58</a>].</p><p>Studies of intratympanic <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> have used different dosing and frequency, and optimal regimens for intratympanic glucocorticoids have not been established.</p><p class="headingAnchor" id="H2659491412"><span class="h3">Refractory, disabling symptoms despite glucocorticoid therapy</span><span class="headingEndMark"> — </span>For patients with refractory MD symptoms and continued poor quality of life despite treatment with systemic or intratympanic glucocorticoids, we offer additional treatments. For all patients, and in particular those patients who have not experienced any improvement with any previous therapy, we also reconsider alternative diagnoses as the cause of their symptoms. (See <a class="local">'Differential diagnosis'</a> above.)</p><p>When considering further treatment for MD, we generally use the degree of labyrinthine function (severity of vertigo attacks and the degree of disequilibrium between attacks) and the level of hearing loss to determine the most appropriate management for an individual patient.</p><p>Treatments include destructive therapies (eg, intratympanic <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, surgical labyrinthectomy, and vestibular neurectomy) which reduce or eliminate signals from the affected labyrinthine system to the brain, and nondestructive procedures (including endolymphatic sac procedures [decompression or shunting or both], sacculotomy) which may reduce the accumulation of fluid in the endolymphatic spaces or otherwise alter fluid and electrolyte physiology in the inner ear; the exact mechanism of their effect is unknown. </p><p>As an example, for patients with preserved hearing in the affected ear, in whom maintenance of hearing is a primary concern, we avoid therapies which may potentially result in hearing loss. Conversely, for patients with complete hearing loss in the affected ear, avoidance of therapies which may cause hearing damage in the treated ear is less of a concern.</p><p>Additionally, treatments that permanently and completely eliminate the labyrinthine signals to the brain are used as a last option for these patients. Although these treatments eliminate the disabling vertigo, the potential future development of MD in the contralateral ear is a concern; in such cases, the patient may be left with no labyrinthine function.</p><p class="headingAnchor" id="H20"><span class="h4">Patients with preserved hearing in affected ear</span></p><p class="bulletIndent1"><span class="glyph">●</span>For MD patients with preserved hearing, refractory vertigo symptoms, and continued poor quality of life despite treatment with systemic or intratympanic glucocorticoids, we offer treatment with endolymphatic sac procedures (including decompression and/or shunting) or sacculotomy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with preserved hearing who have no or inadequate symptomatic improvement from an endolymphatic sac procedure or sacculotomy, we typically then offer treatment with intratympanic gentamycin. In addition, particularly for patients with no response to any previous therapy, we consider an alternative diagnosis as the cause for their symptoms. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If treatment with intratympanic gentamycin is unsuccessful in adequately improving symptoms, we then offer ablative surgery with vestibular neurectomy or labyrinthectomy as a last option.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endolymphatic sac procedures (decompression and/or</strong> <strong>shunting) and sacculotomy</strong> – The nondestructive surgical procedures (including endolymphatic sac procedures [decompression or shunting or both] and sacculotomy) are other treatment options in patients with MD and preserved hearing. Although they are associated with a low risk of sensorineural hearing loss in patients with intact hearing, there are concerns that their efficacy may be due to placebo effect [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent2">These procedures expose the endolymphatic sac and duct, with the aim to improve drainage of endolymph. However, anatomic studies of the endolymphatic sac indicate that such drainage is not plausible [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent2">Two trials have examined the efficacy of these procedures. In one trial of endolymphatic sac decompression, installation of steroids into the sac following drainage did not relieve vertigo symptoms but increased the percent of patients with some hearing improvement [<a href="#rid61">61</a>]. In a trial of endolymphatic shunt surgery using sham surgery as a control, there was no difference in efficacy between groups [<a href="#rid62">62</a>]. However, in subsequent data reanalysis, endolymphatic shunt surgery was superior to sham surgery for control of vertigo, nausea, vomiting, and tinnitus [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent2">In multiple case series, control of vertigo was reported in 75 to 80 percent of patients undergoing these procedures [<a href="#rid61">61,64-67</a>]. Symptomatic improvement in hearing and tinnitus have also been reported with apparent long-term maintenance of these benefits [<a href="#rid61">61,67,68</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intratympanic </strong><a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> – Aminoglycosides are toxic to the sensory neuroepithelium of the inner ear; gentamicin is more vestibulotoxic than cochleotoxic and is the preferred aminoglycoside for intratympanic administration. With this technique, gentamicin is delivered into the middle ear space (by injection or cannula), allowing the drug to locally penetrate the labyrinth through the round window membrane. It destroys hair cells in the semicircular canals, ablating labyrinthine function, theoretically without causing any systemic effects. (See  <a class="medical medical_review" href="/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"</a>.)</p><p></p><p class="bulletIndent2">We administer an initial intratympanic <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> injection (approximately 0.3 mL of a 26 to 40 mg/mL buffered solution, concentration depends upon availability) into the affected ear and may repeat at one week if there is no response to the first injection. If there is some improvement in symptoms, we administer another injection one to two weeks later. We routinely check an audiogram after the second injection or at any point if the patient reports an increase in tinnitus or decrease in hearing.</p><p></p><p class="bulletIndent2">In multiple prospective studies, intratympanic <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> was associated with improved vertigo in 80 to 90 percent of patients with MD [<a href="#rid69">69-73</a>]. However, treatment with intratympanic aminoglycoside is itself associated with a risk of irreversible sensorineural hearing loss in up to 30 percent of patients [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent2">Minimizing the dose of <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> administered may impact vestibular function without affecting cochlear (hearing) function. As examples:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In one prospective study, a single, low-dose transtympanic <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> injection resulted in good control of vertigo in 76 percent of patients followed for four or more years, with minimal hearing loss [<a href="#rid75">75</a>]. A second injection was required to control vertigo symptoms in 15 to 20 percent of patients.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a randomized trial comparing low-dose intratympanic <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> with intratympanic <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, complete vertigo control was greater in the gentamicin group compared with the dexamethasone group (81 versus 43 percent) [<a href="#rid58">58</a>]. Significant hearing loss (&gt;10 dB) occurred in 13 percent of patients in the gentamicin group.</p><p></p><p class="bulletIndent2">There is no consensus regarding the optimal protocol for intratympanic <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> administration, however. As an example, in one meta-analysis, titrating repeated gentamicin doses to vestibular response was superior to other treatment regimens [<a href="#rid76">76</a>]. In another meta-analysis, there was no difference in efficacy between fixed dose and titration regimens, but there were significant quality issues in all included trials [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent2">Despite alterations in regimens meant to mitigate the ototoxicity associated with this treatment, there is no way to completely eliminate the risk of hearing loss associated with IT <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>. Thus, although effective in controlling vertigo, it must be used with caution in patients with preserved hearing.</p><p></p><p class="bulletIndent2">Additionally, despite the low risk of systemic effects (eg, nephrotoxicity) with intratympanic administration, we do not offer intratympanic <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> therapy in patients with significantly impaired kidney function or a solitary functioning kidney.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Labyrinthectomy</strong> – Labyrinthectomy involves surgical destruction of the bony and membranous labyrinth by removal of all of the neuroepithelium from the affected side; this relieves vertigo in virtually all patients but also causes irreversible unilateral hearing loss in all treated patients [<a href="#rid78">78</a>]. Thus, this procedure is only indicated in individuals with significant or complete hearing loss on the affected side, and those who have intractable symptoms despite medical therapy.</p><p></p><p class="bulletIndent2">The concern of many clinicians is that patients may have subclinical disease in the opposite ear that will ultimately progress, and for such patients this may ultimately result in total deafness. While labyrinthectomy is an effective procedure, we avoid this treatment if there is any evidence of MD in the contralateral ear. If the decision is made to proceed with labyrinthectomy, patients should be made aware of the potential risks of future loss of bilateral hearing and vestibular function should MD develop in the contralateral ear. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vestibular neurectomy</strong> – Vestibular neurectomy involves surgical lysis of the vestibular nerve bundle as it enters the internal auditory canal. It relieves vertigo in 90 to 95 percent of patients and is associated with a low risk (10 to 20 percent) of sensorineural hearing loss [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent2">However, vestibular neurectomy requires craniotomy with general anesthesia, requiring overnight intensive care unit monitoring.</p><p></p><p class="bulletIndent2">Concerns over side effects may limit use. However, in a cohort study of patients with unilateral disabling MD treated with vestibular neurotomy, 90.5 percent no longer had vertiginous attacks and there were no drop attacks after an average follow-up of over 12 years. [<a href="#rid79">79</a>]. Furthermore, a separate case series indicated resolution or improvement of vertigo postoperatively in all 12 patients with MD who underwent the procedure with the possibility of using the endoscope as an adjunct in some procedures [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent2">Vestibular neurectomy is reserved for those patients with persistent symptoms despite other treatments, who have relatively preserved of hearing in the affected ear, and who are unwilling to risk the hearing loss associated with intratympanic <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>.</p><p></p><p class="headingAnchor" id="H3737190500"><span class="h4">Patients with complete hearing loss in affected ear</span></p><p class="bulletIndent1"><span class="glyph">●</span>For MD patients with complete hearing loss in the affected hear, refractory vertigo symptoms, and continued poor quality of life despite treatment with systemic or intratympanic glucocorticoids, we suggest intratympanic gentamycin treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If treatment with intratympanic gentamycin is unsuccessful in adequately improving symptoms, we offer ablative surgery with vestibular neurectomy or labyrinthectomy. However, for patients in whom there is no symptomatic response to gentamycin treatment, we consider an alternative diagnosis as the cause for their symptoms before proceeding to surgery. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1328177908"><span class="h1">HEARING AMPLIFICATION FOR HEARING LOSS</span><span class="headingEndMark"> — </span>Hearing aids should be considered for patients with significant binaural hearing loss due to Meniere disease (MD). However, among these patients (particularly early in their disease), hearing fluctuation often leads to frustration with amplification devices and poor patient compliance. Hearing amplification is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6849.html" rel="external">"Hearing amplification in adults"</a>.)</p><p class="headingAnchor" id="H896407206"><span class="h1">THERAPIES THAT WE DO NOT USE</span><span class="headingEndMark"> — </span>There are several therapies used in the treatment of Meniere disease (MD) that we do not routinely use or advise due the lack of efficacy and possible evidence of harm.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive pressure pulse generator</strong> – Positive pressure ("overpressure") applied to the middle ear may improve fluid exchange in the inner ear. Overpressure treatment, in which a device applies pulses of pressure to the middle ear via a ventilation tube, has been used in patients who failed medical therapy or as an adjunct to medical therapy in patients with functional level 3 or greater  (<a class="graphic graphic_table graphicRef72837" href="/d/graphic/72837.html" rel="external">table 4</a>). Maintenance of a patent tympanostomy tube is required for overpressure treatment.</p><p></p><p class="bulletIndent1">Meta-analyses including prospective studies and randomized trials using overpressure in MD are mixed, with one showing improved vertigo symptoms and hearing [<a href="#rid81">81</a>] and another showing no improvement in vertigo and a possible adverse effect on hearing [<a href="#rid82">82</a>]. In addition, the long-term efficacy of overpressure in the control of vertigo is uncertain, and hearing conservation should not be expected in all patients using this therapy.</p><p></p><p class="bulletIndent1">In addition, the pulse generator device is expensive and insurance coverage for this procedure is variable. Thus, out-of-pocket costs may be an additional consideration for use of this therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamins and herbal therapies</strong> – Some patients have reported symptomatic improvement with vitamin regimens and herbal remedies. However, these treatments are not supported by evidence, and we do not advise that patients use these treatments to manage MD [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic immunotherapy</strong> – There are no high-quality data supporting the use of immunosuppressive therapy with low-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid83">83</a>] or <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> [<a href="#rid84">84</a>], and we do not use these medications to treat MD.</p><p></p><p class="headingAnchor" id="H3083468110"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/126560.html" rel="external">"Society guideline links: Hearing loss and hearing disorders in adults"</a>.)</p><p class="headingAnchor" id="H10130196"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83065.html" rel="external">"Patient education: Meniere disease (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/721.html" rel="external">"Patient education: Vertigo (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Meniere disease (MD), characterized by the classic triad of symptoms (episodic vertigo, tinnitus, and hearing loss), is likely caused by endolymphatic hydrops of the labyrinthine system of the inner ear  (<a class="graphic graphic_figure graphicRef126296" href="/d/graphic/126296.html" rel="external">figure 1</a>). (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The course of MD is variable. Some patients experience progressive hearing loss with infrequent vestibular symptoms; some have severe and frequent vertigo with only mild auditory symptoms; and some manifest both auditory and vestibular symptoms in equal measure. Most patients tend to cycle from active symptoms to prolonged remissions. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic criteria</strong> – A clinical diagnosis of MD is made based upon the following criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two or more spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours</p><p class="bulletIndent2"><span class="glyph">•</span>Audiometrically documented low- to mid-frequency sensorineural hearing loss in the affected ear</p><p class="bulletIndent2"><span class="glyph">•</span>Fluctuating aural symptoms (reduced or distorted hearing, tinnitus, or fullness) in the affected ear</p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms not better accounted for by another vestibular diagnosis</p><p></p><p class="bulletIndent1">Although audiometric testing is a required part of the diagnostic evaluation, there is no specific diagnostic test for MD. Imaging, although not required for diagnosis of MD, is frequently performed to exclude important disorders that can present with similar symptoms. (See <a class="local">'Diagnostic criteria and testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – A variety of other conditions can present with symptoms similar to MD and are often considered in the differential diagnosis. The conditions include vestibular migraine, vestibular schwannoma, multiple sclerosis (MS), transient ischemic attacks (TIAs), benign paroxysmal positional vertigo, and Cogan syndrome  (<a class="graphic graphic_table graphicRef63235" href="/d/graphic/63235.html" rel="external">table 2</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary and lifestyle modifications for all patients</strong> – As initial therapy for all patients with MD, we suggest lifestyle modification, including salt restriction, and limiting caffeine and alcohol consumption (to a maximum of one of each beverage daily) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If other triggers are identified (eg, nicotine, stress, monosodium glutamate [MSG]), these should also be avoided. Dietary and lifestyle modifications should be continued indefinitely. (See <a class="local">'Initial diet and lifestyle adjustment for all patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vestibular rehabilitation for persistent disequilibrium</strong> – For patients with MD and persistent disequilibrium symptoms between attacks, we suggest referral for vestibular rehabilitation therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Although vestibular rehabilitation does not reduce the frequency of vertigo attacks, the exercise activities maximize balance and central nervous system (CNS) compensation for disequilibrium symptoms. Vestibular rehabilitation has no role in the treatment of acute vertigo due to MD. (See <a class="local">'Vestibular rehabilitation for residual disequilibrium between attacks'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacotherapy for refractory symptoms</strong> – For all patients with MD with refractory symptoms and poor quality of life despite dietary and lifestyle interventions, we suggest the use of pharmacotherapy rather than no pharmacotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">Betahistine</a> and diuretics are the two options for pharmacologic therapy to reduce the severity and intensity of MD attacks. We suggest treatment with betahistine rather than diuretics, when available (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Betahistine is well tolerated and, unlike diuretics, does not require monitoring of adverse effects such as hypotension, altered kidney function, and electrolyte abnormalities. (See <a class="local">'Chronic management with chronic betahistine or diuretic therapy'</a> above.)</p><p></p><p class="bulletIndent1">For patients who respond to treatment with <a class="drug drug_general" data-topicid="8694" href="/d/drug information/8694.html" rel="external">betahistine</a> or a diuretic, treatment is continued for approximately six months; if symptoms remain well controlled, the medication can be tapered (for betahistine) and discontinued. Pharmacotherapy can be resumed if troublesome symptoms recur.</p><p></p><p class="bulletIndent1">Acute episodes of vertigo should be managed with vestibular suppressants and antiemetics if necessary  (<a class="graphic graphic_table graphicRef68052" href="/d/graphic/68052.html" rel="external">table 3</a>). (See <a class="local">'Acute treatment with vestibular suppressants and antiemetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid therapy (systemic or intratympanic) for persistent symptoms</strong> – Among all patients with refractory symptoms severe enough to require further treatment beyond dietary changes, lifestyle adjustment, and first-line pharmacotherapy, there is no widely accepted agreement upon which treatment is preferred. However, we suggest treatment with glucocorticoids rather than other therapies for these patients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Glucocorticoid therapy for all patients with refractory, disabling symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the majority of patients with MD and refractory, disabling vertigo symptoms despite first-line treatments, we treat with a limited course of oral glucocorticoids.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with MD with disabling vertigo symptoms despite first-line treatments, and in whom oral glucocorticoid therapy is contraindicated, or who through shared decision-making prefer intratympanic therapy, we offer treatment with intratympanic glucocorticoids. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional treatment options for patients refractory to glucocorticoid therapy</strong> – For patients with refractory MD symptoms and continued poor quality of life despite treatment with glucocorticoids (systemic or intratympanic), we offer additional treatments. We generally use the degree of labyrinthine function (severity of vertigo attacks and the degree of disequilibrium between attacks) and the level of hearing loss to determine the most appropriate management for an individual patient. (See <a class="local">'Refractory, disabling symptoms despite glucocorticoid therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For MD patients with preserved hearing, we offer treatment with endolymphatic sac procedures (including decompression and/or shunting) or sacculotomy; if this is unsuccessful, we typically then offer treatment with intratympanic gentamycin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with MD with complete hearing loss in the affected ear, we suggest treatment with IT gentamycin rather than labyrinthectomy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Labyrinthectomy is generally reserved for those patients who have disabling symptoms that persist despite treatment with IT <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>. (See <a class="local">'Patients with complete hearing loss in affected ear'</a> above.)</p><p></p><p class="headingAnchor" id="H26211729"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Steven Rauch, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Meniere P. Congestions cerebrales apoplectiformes. Gaz md Paris 1861; 16:55.</a></li><li><a class="nounderline abstract_t">Meyerhoff WL, Paparella MM, Shea D. Ménière's disease in children. Laryngoscope 1978; 88:1504.</a></li><li><a class="nounderline abstract_t">Jackler RK, Luxford WM, Brackmann DE, Monsell EM. Endolymphatic sac surgery in congenital malformations of the inner ear. Laryngoscope 1988; 98:698.</a></li><li class="breakAll">Schessel DA, Minor LB, Nedzelski J. Meniere's disease and other peripheral vestibular disorders. In: Otolaryngology Head and Neck Surgery, Cummings CW (Ed), Mosby, St. Louis 1998. p.2672.</li><li><a class="nounderline abstract_t">Balkany TJ, Sires B, Arenberg IK. Bilateral aspects of Meniere's disease: an underestimated clinical entity. Otolaryngol Clin North Am 1980; 13:603.</a></li><li><a class="nounderline abstract_t">Enander A, Stahle J. Hearing in Menière's disease. A study of pure-tone audiograms in 334 patients. Acta Otolaryngol 1967; 64:543.</a></li><li><a class="nounderline abstract_t">Mizukoshi K, Ino H, Ishikawa K, et al. Epidemiological survey of definite cases of Meniere's disease collected by the seventeen members of the Meniere's Disease Research Committee of Japan in 1975--1976. Adv Otorhinolaryngol 1979; 25:106.</a></li><li><a class="nounderline abstract_t">Zhang W, Hui L, Zhang B, et al. The Correlation Between Endolymphatic Hydrops and Clinical Features of Meniere Disease. Laryngoscope 2021; 131:E144.</a></li><li><a class="nounderline abstract_t">Coelho DH, Lalwani AK. Medical management of Ménière's disease. Laryngoscope 2008; 118:1099.</a></li><li><a class="nounderline abstract_t">Kimura RS. Experimental blockage of the endolymphatic duct and sac and its effect on the inner ear of the guinea pig. A study on endolymphatic hydrops. Ann Otol Rhinol Laryngol 1967; 76:664.</a></li><li><a class="nounderline abstract_t">Hornibrook J, Bird P. A New Theory for Ménière's Disease. Otolaryngol Head Neck Surg 2017; 156:350.</a></li><li><a class="nounderline abstract_t">Yamamoto E, Mizukami C. Development of the vestibular aqueduct in Menière's disease. Acta Otolaryngol Suppl 1993; 504:46.</a></li><li><a class="nounderline abstract_t">Alleman AM, Dornhoffer JL, Arenberg IK, Walker PD. Demonstration of autoantibodies to the endolymphatic sac in Meniere's disease. Laryngoscope 1997; 107:211.</a></li><li><a class="nounderline abstract_t">Evans KL, Baldwin DL, Bainbridge D, Morrison AW. Immune status in patients with Menière's disease. Arch Otorhinolaryngol 1988; 245:287.</a></li><li><a class="nounderline abstract_t">Brookes GB. Circulating immune complexes in Meniere's disease. Arch Otolaryngol Head Neck Surg 1986; 112:536.</a></li><li><a class="nounderline abstract_t">Morrison AW. Anticipation in Menière's disease. J Laryngol Otol 1995; 109:499.</a></li><li><a class="nounderline abstract_t">Klockars T, Kentala E. Inheritance of Meniere's disease in the Finnish population. Arch Otolaryngol Head Neck Surg 2007; 133:73.</a></li><li><a class="nounderline abstract_t">Parker W. Menière's disease. Etiologic considerations. Arch Otolaryngol Head Neck Surg 1995; 121:377.</a></li><li><a class="nounderline abstract_t">Radtke A, Lempert T, Gresty MA, et al. Migraine and Ménière's disease: is there a link? Neurology 2002; 59:1700.</a></li><li><a class="nounderline abstract_t">Perez-Garrigues H, Lopez-Escamez JA, Perez P, et al. Time course of episodes of definitive vertigo in Meniere's disease. Arch Otolaryngol Head Neck Surg 2008; 134:1149.</a></li><li><a class="nounderline abstract_t">Saeed SR. Fortnightly review. Diagnosis and treatment of Ménière's disease. BMJ 1998; 316:368.</a></li><li><a class="nounderline abstract_t">Hoa M, Friedman RA, Fisher LM, Derebery MJ. Prognostic implications of and audiometric evidence for hearing fluctuation in Meniere's disease. Laryngoscope 2015; 125 Suppl 12:S1.</a></li><li><a class="nounderline abstract_t">Basura GJ, Adams ME, Monfared A, et al. Clinical Practice Guideline: Ménière's Disease Executive Summary. Otolaryngol Head Neck Surg 2020; 162:415.</a></li><li><a class="nounderline abstract_t">Lopez-Escamez JA, Carey J, Chung WH, et al. Diagnostic criteria for Menière's disease. J Vestib Res 2015; 25:1.</a></li><li><a class="nounderline abstract_t">Goebel JA. 2015 Equilibrium Committee Amendment to the 1995 AAO-HNS Guidelines for the Definition of Ménière's Disease. Otolaryngol Head Neck Surg 2016; 154:403.</a></li><li><a class="nounderline abstract_t">Harcourt J, Barraclough K, Bronstein AM. Meniere's disease. BMJ 2014; 349:g6544.</a></li><li><a class="nounderline abstract_t">Lorenzi MC, Bento RF, Daniel MM, Leite CC. Magnetic resonance imaging of the temporal bone in patients with Ménière's disease. Acta Otolaryngol 2000; 120:615.</a></li><li><a class="nounderline abstract_t">Gottschlich S, Billings PB, Keithley EM, et al. Assessment of serum antibodies in patients with rapidly progressive sensorineural hearing loss and Menière's disease. Laryngoscope 1995; 105:1347.</a></li><li><a class="nounderline abstract_t">Bloch DB, San Martin JE, Rauch SD, et al. Serum antibodies to heat shock protein 70 in sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 1995; 121:1167.</a></li><li><a class="nounderline abstract_t">Shin SO, Billings PB, Keithley EM, Harris JP. Comparison of anti-heat shock protein 70 (anti-hsp70) and anti-68-kDa inner ear protein in the sera of patients with Meniere's disease. Laryngoscope 1997; 107:222.</a></li><li><a class="nounderline abstract_t">Yen PT, Lin CC, Huang TS. A preliminary report on the correlation of vestibular Meniére's disease with electrocochleography and glycerol test. Acta Otolaryngol Suppl 1995; 520 Pt 2:241.</a></li><li><a class="nounderline abstract_t">Conlon BJ, Gibson WP. Electrocochleography in the diagnosis of Meniere's disease. Acta Otolaryngol 2000; 120:480.</a></li><li><a class="nounderline abstract_t">Rauch SD, Zhou G, Kujawa SG, et al. Vestibular evoked myogenic potentials show altered tuning in patients with Ménière's disease. Otol Neurotol 2004; 25:333.</a></li><li><a class="nounderline abstract_t">Lin MY, Timmer FC, Oriel BS, et al. Vestibular evoked myogenic potentials (VEMP) can detect asymptomatic saccular hydrops. Laryngoscope 2006; 116:987.</a></li><li><a class="nounderline abstract_t">Taylor RL, Wijewardene AA, Gibson WP, et al. The vestibular evoked-potential profile of Ménière's disease. Clin Neurophysiol 2011; 122:1256.</a></li><li><a class="nounderline abstract_t">Wladislavosky-Waserman P, Facer GW, Mokri B, Kurland LT. Meniere's disease: a 30-year epidemiologic and clinical study in Rochester, Mn, 1951-1980. Laryngoscope 1984; 94:1098.</a></li><li><a class="nounderline abstract_t">Boyev KP. Meniere's disease or migraine? The clinical significance of fluctuating hearing loss with vertigo. Arch Otolaryngol Head Neck Surg 2005; 131:457.</a></li><li><a class="nounderline abstract_t">Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.</a></li><li><a class="nounderline abstract_t">Thorp MA, Shehab ZP, Bance ML, Rutka JA. Does evidence-based medicine exist in the treatment of Menière's disease? A critical review of the last decade of publications. Clin Otolaryngol Allied Sci 2000; 25:456.</a></li><li><a class="nounderline abstract_t">Hussain K, Murdin L, Schilder AG. Restriction of salt, caffeine and alcohol intake for the treatment of Ménière's disease or syndrome. Cochrane Database Syst Rev 2018; 12:CD012173.</a></li><li><a class="nounderline abstract_t">Santos PM, Hall RA, Snyder JM, et al. Diuretic and diet effect on Menière's disease evaluated by the 1985 Committee on Hearing and Equilibrium guidelines. Otolaryngol Head Neck Surg 1993; 109:680.</a></li><li><a class="nounderline abstract_t">Boles R, Rice DH, Hybels R, Work WP. Conservative management of Méniére's disease: Furstenberg regimen revisited. Ann Otol Rhinol Laryngol 1975; 84:513.</a></li><li><a class="nounderline abstract_t">Gottshall KR, Hoffer ME, Moore RJ, Balough BJ. The role of vestibular rehabilitation in the treatment of Meniere's disease. Otolaryngol Head Neck Surg 2005; 133:326.</a></li><li><a class="nounderline abstract_t">Kinney SE, Sandridge SA, Newman CW. Long-term effects of Ménière's disease on hearing and quality of life. Am J Otol 1997; 18:67.</a></li><li><a class="nounderline abstract_t">Ganança MM, Caovilla HH, Ganança FF. Comparable efficacy and tolerability between twice daily and three times daily betahistine for Ménière's disease. Acta Otolaryngol 2009; 129:487.</a></li><li><a class="nounderline abstract_t">Claes J, Van de Heyning PH. A review of medical treatment for Ménière's disease. Acta Otolaryngol Suppl 2000; 544:34.</a></li><li><a class="nounderline abstract_t">Thirlwall AS, Kundu S. Diuretics for Ménière's disease or syndrome. Cochrane Database Syst Rev 2006; :CD003599.</a></li><li><a class="nounderline abstract_t">James AL, Burton MJ. Betahistine for Menière's disease or syndrome. Cochrane Database Syst Rev 2001; :CD001873.</a></li><li><a class="nounderline abstract_t">Adrion C, Fischer CS, Wagner J, et al. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 2016; 352:h6816.</a></li><li><a class="nounderline abstract_t">Martinez DM. The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals. Acta Otolaryngol Suppl 1972; 305:29.</a></li><li><a class="nounderline abstract_t">Timmerman H. Pharmacotherapy of vertigo: any news to be expected? Acta Otolaryngol Suppl 1994; 513:28.</a></li><li><a class="nounderline abstract_t">Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995; 113:181.</a></li><li><a class="nounderline abstract_t">Morales-Luckie E, Cornejo-Suarez A, Zaragoza-Contreras MA, Gonzalez-Perez O. Oral administration of prednisone to control refractory vertigo in Ménière's disease: a pilot study. Otol Neurotol 2005; 26:1022.</a></li><li><a class="nounderline abstract_t">Martin-Sanz E, Esteban-Sanchez J, Rodrigañez-Riesco L, Sanz-Fernández R. Transitory effect on endolymphatic hydrops of the intratympanic steroids for Ménière's disease. Laryngoscope 2015; 125:1183.</a></li><li><a class="nounderline abstract_t">Garduño-Anaya MA, Couthino De Toledo H, Hinojosa-González R, et al. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005; 133:285.</a></li><li><a class="nounderline abstract_t">Barrs DM, Keyser JS, Stallworth C, McElveen JT Jr. Intratympanic steroid injections for intractable Ménière's disease. Laryngoscope 2001; 111:2100.</a></li><li><a class="nounderline abstract_t">Boleas-Aguirre MS, Lin FR, Della Santina CC, et al. Longitudinal results with intratympanic dexamethasone in the treatment of Ménière's disease. Otol Neurotol 2008; 29:33.</a></li><li><a class="nounderline abstract_t">Casani AP, Piaggi P, Cerchiai N, et al. Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol Head Neck Surg 2012; 146:430.</a></li><li><a class="nounderline abstract_t">Kim HH, Wiet RJ, Battista RA. Trends in the diagnosis and the management of Meniere's disease: results of a survey. Otolaryngol Head Neck Surg 2005; 132:722.</a></li><li><a class="nounderline abstract_t">Friberg U, Jansson B, Rask-Andersen H, Bagger-Sjöbäck D. Variations in surgical anatomy of the endolymphatic sac. Arch Otolaryngol Head Neck Surg 1988; 114:389.</a></li><li><a class="nounderline abstract_t">Kitahara T, Kubo T, Okumura S, Kitahara M. Effects of endolymphatic sac drainage with steroids for intractable Meniere's disease: a long-term follow-up and randomized controlled study. Laryngoscope 2008; 118:854.</a></li><li><a class="nounderline abstract_t">Thomsen J, Bretlau P, Tos M, Johnsen NJ. Placebo effect in surgery for Ménière's disease. A double-blind, placebo-controlled study on endolymphatic sac shunt surgery. Arch Otolaryngol 1981; 107:271.</a></li><li><a class="nounderline abstract_t">Welling DB, Nagaraja HN. Endolymphatic mastoid shunt: a reevaluation of efficacy. Otolaryngol Head Neck Surg 2000; 122:340.</a></li><li><a class="nounderline abstract_t">Moffat DA. Endolymphatic sac surgery: analysis of 100 operations. Clin Otolaryngol Allied Sci 1994; 19:261.</a></li><li><a class="nounderline abstract_t">Telischi FF, Luxford WM. Long-term efficacy of endolymphatic sac surgery for vertigo in Menière's disease. Otolaryngol Head Neck Surg 1993; 109:83.</a></li><li><a class="nounderline abstract_t">Brinson GM, Chen DA, Arriaga MA. Endolymphatic mastoid shunt versus endolymphatic sac decompression for Ménière's disease. Otolaryngol Head Neck Surg 2007; 136:415.</a></li><li><a class="nounderline abstract_t">Wetmore SJ. Endolymphatic sac surgery for Ménière's disease: long-term results after primary and revision surgery. Arch Otolaryngol Head Neck Surg 2008; 134:1144.</a></li><li><a class="nounderline abstract_t">Ostrowski VB, Kartush JM. Endolymphatic sac-vein decompression for intractable Meniere's disease: long term treatment results. Otolaryngol Head Neck Surg 2003; 128:550.</a></li><li><a class="nounderline abstract_t">Nedzelski JM, Schessel DA, Bryce GE, Pfleiderer AG. Chemical labyrinthectomy: local application of gentamicin for the treatment of unilateral Menière's disease. Am J Otol 1992; 13:18.</a></li><li><a class="nounderline abstract_t">Quaranta A, Aloisi A, De Benedittis G, Scaringi A. Intratympanic therapy for Ménière's disease. High-concentration gentamicin with round-window protection. Ann N Y Acad Sci 1999; 884:410.</a></li><li><a class="nounderline abstract_t">Perez N, Martín E, García-Tapia R. Intratympanic gentamicin for intractable Meniere's disease. Laryngoscope 2003; 113:456.</a></li><li><a class="nounderline abstract_t">Boleas-Aguirre MS, Sánchez-Ferrandiz N, Guillén-Grima F, Perez N. Long-term disability of class A patients with Ménière's disease after treatment with intratympanic gentamicin. Laryngoscope 2007; 117:1474.</a></li><li><a class="nounderline abstract_t">Rah YC, Han JJ, Park J, et al. Management of intractable Ménière's disease after intratympanic injection of gentamicin. Laryngoscope 2015; 125:972.</a></li><li><a class="nounderline abstract_t">Blakley BW. Update on intratympanic gentamicin for Meniere's disease. Laryngoscope 2000; 110:236.</a></li><li><a class="nounderline abstract_t">Harner SG, Driscoll CL, Facer GW, et al. Long-term follow-up of transtympanic gentamicin for Ménière's syndrome. Otol Neurotol 2001; 22:210.</a></li><li><a class="nounderline abstract_t">Chia SH, Gamst AC, Anderson JP, Harris JP. Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis. Otol Neurotol 2004; 25:544.</a></li><li><a class="nounderline abstract_t">Cohen-Kerem R, Kisilevsky V, Einarson TR, et al. Intratympanic gentamicin for Menière's disease: a meta-analysis. Laryngoscope 2004; 114:2085.</a></li><li><a class="nounderline abstract_t">Gacek RR, Gacek MR. Comparison of labyrinthectomy and vestibular neurectomy in the control of vertigo. Laryngoscope 1996; 106:225.</a></li><li><a class="nounderline abstract_t">Véleine Y, Brenet E, Labrousse M, et al. Long-term efficacy of vestibular neurotomy in disabling Ménière's disease and Tumarkin drop attacks. J Neurosurg 2022; :1.</a></li><li><a class="nounderline abstract_t">Chen BS, Roberts DS, Lekovic GP. Vestibular Neurectomy for Intractable Vertigo: Case Series and Evaluation of Role of Endoscopic Assistance in Retrolabyrinthine Craniotomy. J Neurol Surg B Skull Base 2019; 80:357.</a></li><li><a class="nounderline abstract_t">Ahsan SF, Standring R, Wang Y. Systematic review and meta-analysis of Meniett therapy for Meniere's disease. Laryngoscope 2015; 125:203.</a></li><li><a class="nounderline abstract_t">van Sonsbeek S, Pullens B, van Benthem PP. Positive pressure therapy for Ménière's disease or syndrome. Cochrane Database Syst Rev 2015; :CD008419.</a></li><li><a class="nounderline abstract_t">Kilpatrick JK, Sismanis A, Spencer RF, Wise CM. Low-dose oral methotrexate management of patients with bilateral Ménière's disease. Ear Nose Throat J 2000; 79:82.</a></li><li><a class="nounderline abstract_t">Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol 2001; 22:619.</a></li></ol></div><div id="topicVersionRevision">Topic 6859 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Congestions cerebrales apoplectiformes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/682806" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ménière's disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3386372" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Endolymphatic sac surgery in congenital malformations of the inner ear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3386372" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Endolymphatic sac surgery in congenital malformations of the inner ear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7454321" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bilateral aspects of Meniere's disease: an underestimated clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6083380" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hearing in Menière's disease. A study of pure-tone audiograms in 334 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/484342" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiological survey of definite cases of Meniere's disease collected by the seventeen members of the Meniere's Disease Research Committee of Japan in 1975--1976.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32083730" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Correlation Between Endolymphatic Hydrops and Clinical Features of Meniere Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18418279" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Medical management of Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6046009" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Experimental blockage of the endolymphatic duct and sac and its effect on the inner ear of the guinea pig. A study on endolymphatic hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28145833" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A New Theory for Ménière's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8470532" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Development of the vestibular aqueduct in Menière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9023245" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Demonstration of autoantibodies to the endolymphatic sac in Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3245800" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Immune status in patients with Menière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3485438" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Circulating immune complexes in Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7642988" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Anticipation in Menière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224529" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inheritance of Meniere's disease in the Finnish population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7702810" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Menière's disease. Etiologic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12473755" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Migraine and Ménière's disease: is there a link?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19015442" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Time course of episodes of definitive vertigo in Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9487176" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fortnightly review. Diagnosis and treatment of Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26343803" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prognostic implications of and audiometric evidence for hearing fluctuation in Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32267820" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical Practice Guideline: Ménière's Disease Executive Summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25882471" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnostic criteria for Menière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884364" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 2015 Equilibrium Committee Amendment to the 1995 AAO-HNS Guidelines for the Definition of Ménière's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25391837" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11039871" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Magnetic resonance imaging of the temporal bone in patients with Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8523990" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Assessment of serum antibodies in patients with rapidly progressive sensorineural hearing loss and Menière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7546586" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Serum antibodies to heat shock protein 70 in sensorineural hearing loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9023247" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of anti-heat shock protein 70 (anti-hsp70) and anti-68-kDa inner ear protein in the sera of patients with Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8749129" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A preliminary report on the correlation of vestibular Meniére's disease with electrocochleography and glycerol test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10958398" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Electrocochleography in the diagnosis of Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15129114" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vestibular evoked myogenic potentials show altered tuning in patients with Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735912" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vestibular evoked myogenic potentials (VEMP) can detect asymptomatic saccular hydrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21168362" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The vestibular evoked-potential profile of Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6611471" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Meniere's disease: a 30-year epidemiologic and clinical study in Rochester, Mn, 1951-1980.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897428" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Meniere's disease or migraine? The clinical significance of fluctuating hearing loss with vertigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14979299" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The International Classification of Headache Disorders: 2nd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122279" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Does evidence-based medicine exist in the treatment of Menière's disease? A critical review of the last decade of publications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30596397" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Restriction of salt, caffeine and alcohol intake for the treatment of Ménière's disease or syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8233504" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diuretic and diet effect on Menière's disease evaluated by the 1985 Committee on Hearing and Equilibrium guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1155886" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Conservative management of Méniére's disease: Furstenberg regimen revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143175" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The role of vestibular rehabilitation in the treatment of Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989954" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term effects of Ménière's disease on hearing and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18615332" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparable efficacy and tolerability between twice daily and three times daily betahistine for Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10904799" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A review of medical treatment for Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856015" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Diuretics for Ménière's disease or syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279734" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Betahistine for Menière's disease or syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797774" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4353749" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910713" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pharmacotherapy of vertigo: any news to be expected?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7675476" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151353" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Oral administration of prednisone to control refractory vertigo in Ménière's disease: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25429741" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Transitory effect on endolymphatic hydrops of the intratympanic steroids for Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087029" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11802004" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intratympanic steroid injections for intractable Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199956" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Longitudinal results with intratympanic dexamethasone in the treatment of Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22101095" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886625" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Trends in the diagnosis and the management of Meniere's disease: results of a survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3348894" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Variations in surgical anatomy of the endolymphatic sac.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520184" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effects of endolymphatic sac drainage with steroids for intractable Meniere's disease: a long-term follow-up and randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7013741" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Placebo effect in surgery for Ménière's disease. A double-blind, placebo-controlled study on endolymphatic sac shunt surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699806" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Endolymphatic mastoid shunt: a reevaluation of efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7923853" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Endolymphatic sac surgery: analysis of 100 operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8336972" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term efficacy of endolymphatic sac surgery for vertigo in Menière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321870" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Endolymphatic mastoid shunt versus endolymphatic sac decompression for Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19015441" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Endolymphatic sac surgery for Ménière's disease: long-term results after primary and revision surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707660" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Endolymphatic sac-vein decompression for intractable Meniere's disease: long term treatment results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1598978" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chemical labyrinthectomy: local application of gentamicin for the treatment of unilateral Menière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10842610" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Intratympanic therapy for Ménière's disease. High-concentration gentamicin with round-window protection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12616197" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intratympanic gentamicin for intractable Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17607149" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term disability of class A patients with Ménière's disease after treatment with intratympanic gentamicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25363447" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Management of intractable Ménière's disease after intratympanic injection of gentamicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10680922" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Update on intratympanic gentamicin for Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11300271" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term follow-up of transtympanic gentamicin for Ménière's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15241234" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564826" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Intratympanic gentamicin for Menière's disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8583859" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparison of labyrinthectomy and vestibular neurectomy in the control of vertigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34996039" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Long-term efficacy of vestibular neurotomy in disabling Ménière's disease and Tumarkin drop attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31328081" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Vestibular Neurectomy for Intractable Vertigo: Case Series and Evaluation of Role of Endoscopic Assistance in Retrolabyrinthine Craniotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24913022" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Systematic review and meta-analysis of Meniett therapy for Meniere's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25756795" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Positive pressure therapy for Ménière's disease or syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10697931" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Low-dose oral methotrexate management of patients with bilateral Ménière's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11568668" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
